Investigation of the pharmacokinetics of gemcitabine and 2′,2′-difluorodeoxyuridine in human plasma by liquid chromatography

Analytical Biochemistry

Volumn 332, Issue 2, 2004, Pages 234-237

  Yilmaz, Bilal ^a   Kadioǧlu, Yücel ^a   Aksoy, Yilmaz ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

2 ,2 Difluorodeoxyuridine; Gemcitabine; Plasma pharmacokinetics

Indexed keywords

DISEASES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLITES; PATIENT TREATMENT;

ANTI-TUMOR ACTIVITIES; BLADDER CANCERS; GEMCITABINE; HUMAN PLASMAS; OPEN MODELING METHODS; PLASMA CONCENTRATION; PLASMA SAMPLES; SOLID TUMORS;

PHARMACOKINETICS;

ANTINEOPLASTIC AGENT; DEOXYURIDINE DERIVATIVE; GEMCITABINE;

AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CASE REPORT; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL;

EID: 8444237000     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ab.2004.05.059     Document Type: Article

References (20)

1. W. Plunkett, P. Huang, Y.Z. Xu, V. Heinemann, R. Grunewald, and V. Gandhi Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin. Oncol. 22 1995 3 10
2. V. Gandhi, and W. Plunkett Modulatory activity of 2′,2′- difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides Cancer Res. 50 1990 3675
3. V. Heineman, L.W. Hertel, G.B. Grindey, and W. Plunkett Comparison of the cellular pharmacokinetics and toxicity of 2′,2′- difluorodeoxycytidine and 1-β-d-arabinofuranosylcytosine Cancer Res. 48 1998 4024
4. R. Abratt, W. Bezwoda, G. Falkson, L. Goedhals, D. Hacking, and T. Rugg Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study J. Clin. Oncol. 12 1994 1535
5. J. Carmichael, K. Possinger, P. Phillip, M. Beykirch, H. Kerr, J. Walling, and A. Harris Advanced breast cancer: a phase II trial with gemcitabine J. Clin. Oncol. 13 1995 2731
6. J. Carmichael, and J. Walling Phase II activity of gemcitabine in advanced breast cancer Semin. Oncol. 23 1996 77
7. L. Hertel, G. Boder, J. Kroin, S. Rinzel, G. Poore, G. Todd, and G. Grindey Evaluation of the antitumor activity of gemcitabine (2′,2′- difluorodeoxycytidine) Cancer Res. 50 1990 4417
8. K. Possinger, M. Kaufmann, R. Coleman, N. Stuart, M. Helsing, U. Ohnmacht, and M. Arning Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer Anticancer Drugs 10 1999 155
9. P. Schmid, K. Akrivakis, B. Flath, Y. Grosse, O. Sezer, H. Mergenthaler, and K. Possinger Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer Anticancer Drugs 10 1999 625
10. C.J.A. Van Moorsel, G.J. Peters, and H.M. Pinedo Gemcitabine; future prospects of single-agents and combination studies Oncologist 2 1997 127
11. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics CA Cancer J. Clin. 49 1999 8
12. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, B. Nowak, S. Mineishi, P. Tarassoff, W. Satterlee, M.N. Raber, and W. Plunkett A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J. Clin. Oncol. 9 1991 491
13. R. Grunewald, H. Kantarjian, M. Keating, J. Abruzzese, P. Tarassoff, and W. Plunkett Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia Cancer Res. 50 1990 6823
14. R. Grunewald, H. Kantarjian, M. Du, K. Faucher, P. Tarassoff, and W. Plunkett Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study J. Clin. Oncol. 10 1992 406
15. S. Safgren, J. Holcenberg, P. Steinherz, J. Reid, N. Seibel, G. Reaman, and M. Ames Gemcitabine pharmacokinetics in pediatric patients with solid tumors, leukemia, and non-Hodgkin's lymphoma: a children's cancer group study Proc. Am. Assoc. Cancer Res. 41 2000 416
16. B. YIlmaz, Y.Y. KadIoǧlu, and Y. Aksoy Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography J. Chromatogr. B 791 1-2 2003 103
17. J.Z. Kerr, S.L. Berg, R. Dauser, J. Nuchtern, M.J. Egorin, L. McGuffey, A. Alleksic, and S. Blaney Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates Cancer Chemother. Pharmacol. 47 2001 411
18. J.R. Kroep, G. Giaccone, D.A. Voorn, E. Smit, J.H. Beijnen, and H. Rosing Gemcitabine and paclitaxel; pharmacokinetic and pharmacodinamic interactions in parents with non-small cell lung cancer J. Clin. Oncol. 17 1999 2190
19. B.J. Delauter, R.K. Ramanathan, M.J. Egorin, L.L. Stover, E.G. Zuhowski, W. Plunkett, and W.C. Zamboni Pharmacokinetics of gemcitabine and 2′,2′-difluorodeoxyuridine in a patient with ascites Pharmacotherapy 20 2000 1204
20. S. Fogli, R. Danesi, F.D. Braud, T.D. Pas, G. Curigliano, E. Giovannetti, and M.D. Taca Drug distribution and pharmacokinetic/pharmacodynamic relations of paclitaxel and gemcitabine in patients with non-small-cell lung cancer Ann. Oncol. 12 2001 1553